Table 2.
Characteristics of severe COVID-19 patients with hypertension between survivors and non-survivors.
| Survivors (n = 105) | Non-survivors (n = 21) | p value | |
|---|---|---|---|
| Age, mean (SD), years | 65.4 (10.6) | 70.8 (9.4) | 0.035 |
| ≤70 | 70 (66.7) | 10 (47.6) | 0.098 |
| >70 | 35 (33.3) | 11 (52.4) | |
| Sex, male, n (%) | 40 (38.1) | 16 (76.2) | 0.001 |
| Other comorbidities, n (%) | |||
| Diabetes | 36 (34.3) | 5 (23.8) | 0.350 |
| Coronary artery disease | 16 (15.2) | 5 (23.8) | 0.344 |
| Chronic pulmonary disease | 5 (4.8) | 3 (14.3) | 0.128 |
| Cerebrovascular disease | 10 (9.5) | 0 (0) | 0.211 |
| Malignant tumors | 7 (6.7) | 1 (4.8) | 1.000 |
| Chronic hepatorenal disease | 1 (1.0) | 2 (9.5) | 0.072 |
| Symptoms, n (%) | |||
| Fever | 78 (74.3) | 18 (85.7) | 0.262 |
| Cough | 70 (66.7) | 16 (76.2) | 0.392 |
| Expectoration | 31 (29.5) | 8 (38.1) | 0.438 |
| Fatigue | 46 (43.8) | 10 (47.6) | 0.748 |
| Chill | 20 (19.0) | 6 (28.6) | 0.377 |
| Anorexia | 22 (21.0) | 8 (38.1) | 0.092 |
| Myalgia | 21 (20.0) | 7 (33.3) | 0.248 |
| Dyspnea | 54 (51.4) | 15 (71.4) | 0.093 |
| Pharyngalgia | 6 (5.7) | 1 (4.8) | 1.000 |
| Diarrhea | 37 (35.2) | 8 (38.1) | 0.803 |
| Time from onset to admission, median (IQR), days | 10 (5.5–14.0) | 7 (5.0–10.5) | 0.425 |
| ≥10 | 53 (50.5) | 6 (38.1) | 0.300 |
| <10 | 52 (49.5) | 13 (61.9) | |
| Treatment, n (%) | |||
| ACEI/ARB administration | 31 (29.5) | 6 (28.6) | 0.930 |
| Beta-blocker | 14 (13.3) | 1 (4.8) | 0.463 |
| CCB | 81 (77.1) | 15 (71.4) | 0.575 |
| Diuretic | 5 (4.8) | 0 (0) | 0.589 |
| Statins | 9 (8.6) | 2 (9.5) | 1.000 |
| Antidiabetic | 26 (24.8) | 4 (19.0) | 0.575 |
| Antiplatelet drugs | 14 (13.3) | 4 (19.0) | 0.500 |
COVID-19, coronavirus disease 2019; SD, standard deviation; IQR, interquartile range; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers.